TransMedics Group (NASDAQ:TMDX) Earns Buy Rating from Canaccord Genuity Group

TransMedics Group (NASDAQ:TMDX)‘s stock had its “buy” rating restated by research analysts at Canaccord Genuity Group in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $124.00 price target on the stock. Canaccord Genuity Group’s target price indicates a potential upside of 88.28% from the stock’s previous close.

Several other research analysts have also recently weighed in on TMDX. Stifel Nicolaus boosted their price target on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a report on Thursday, June 18th. Oppenheimer lowered shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 6th. TD Cowen dropped their target price on shares of TransMedics Group from $190.00 to $120.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Needham & Company LLC cut their target price on TransMedics Group from $174.00 to $142.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Finally, Wall Street Zen lowered TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Six equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $134.50.

TransMedics Group Stock Down 2.1%

NASDAQ TMDX traded down $1.43 on Tuesday, reaching $65.86. The company had a trading volume of 461,279 shares, compared to its average volume of 1,106,508. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. The company’s fifty day moving average is $78.65 and its 200 day moving average is $109.80. TransMedics Group has a 52-week low of $60.10 and a 52-week high of $156.00. The stock has a market capitalization of $2.28 billion, a P/E ratio of 14.92 and a beta of 1.92.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The firm had revenue of $173.93 million for the quarter, compared to analysts’ expectations of $174.44 million. During the same period in the prior year, the firm earned $0.70 earnings per share. TransMedics Group’s revenue was up 21.2% compared to the same quarter last year. Sell-side analysts anticipate that TransMedics Group will post 1.98 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Thomas J. Gunderson sold 9,624 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the sale, the director owned 16,642 shares in the company, valued at $1,249,148.52. This trade represents a 36.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently bought and sold shares of the company. D.A. Davidson & CO. increased its stake in TransMedics Group by 0.5% in the 4th quarter. D.A. Davidson & CO. now owns 15,334 shares of the company’s stock worth $1,865,000 after acquiring an additional 83 shares during the last quarter. Parallel Advisors LLC boosted its position in shares of TransMedics Group by 42.1% during the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after acquiring an additional 83 shares during the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of TransMedics Group by 4.0% during the fourth quarter. Crossmark Global Holdings Inc. now owns 2,275 shares of the company’s stock worth $277,000 after purchasing an additional 88 shares in the last quarter. HighPoint Advisor Group LLC grew its holdings in shares of TransMedics Group by 3.1% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,955 shares of the company’s stock worth $359,000 after purchasing an additional 88 shares in the last quarter. Finally, Canada Pension Plan Investment Board grew its holdings in shares of TransMedics Group by 2.9% during the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock worth $482,000 after purchasing an additional 100 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.